SP, page-28

Given the response to the price query I would suggest it is more likely that the price has increased due to a a few institutions taking a position. There may be a few reasons for their decision on this;
1. I agree with the above on earnings increases due to USD increases
2. The FDA 510(K) clearance which will allow them to convey more data resulting in a higher charge rate per scan (This was flagged in management presentations as a strategy). A $1 increase increases the cost from $3+/- to $4+/- which is a basic uplift of 33% per scan
3. Expected increase of scans to 9%+ of US total mammograms.

I think if you look at cash receipts which in last quarterly were up 16% at $1m NZD add in 16% growth (Last quarter increase), then add in a 10% fall in NZDUSD you would see a likely uplift in quarterly ahead of expectations- Not to mention a possible uplift from a price increase. It would be great to also see an increase in total scans by more than the previous quarter to demonstrate the start of a more exponential growth phase as it gets widely adopted. At this time it would be good to see management upgrade their guidance beyond the 9% target. I would suggest you take the above as an attempt to rationalise the recent gains rather than what I believe will happen